Certain therapies used for rheumatic diseases, including rituximab, are associated with worse outcomes for COVID-19 and reduced immune response after COVID-19 vaccination in patients with rheumatic diseases, according to two studies presented at the virtual EULAR 2021 Congress.
Treatment with the fully human anti-IL17 monoclonal antibody secukinumab resulted in fewer, and a longer time to, disease flares in children and adolescents with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), results of the phase III JUNIPERA trial showed.
Treatment with guselkumab improved response rates in patients with active psoriatic arthritis (PsA) who had inadequate responses to tumour necrosis factor (TNF) inhibitors, according to the COSMOS* study presented at EULAR 2021.
The human monoclonal antibody mavrilimumab reduced the rates of mechanical ventilation and death in nonmechanically ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation, according to a phase II/III study presented at EULAR 2021.
The humanized immunoglobulin G1 monoclonal antibody risankizumab led to significant improvements in patients with active psoriatic arthritis (PsA), including those with insufficient response or intolerance to one or two biologic therapies or to at least one DMARD*, according to the results of the phase III KEEPsAKE2 trial presented at EULAR 2021.
A high dose of the high-affinity cereblon ligand iberdomide delivered beneficial effects on the cutaneous manifestations of systemic lupus erythematosus (SLE), according to a phase II study presented at EULAR 2021.
Exposure to secondhand smoke, regardless of whether it is during childhood or adulthood, is associated with an increased risk of developing rheumatoid arthritis (RA) among women — particularly in those who never smoke themselves, according to data from the E3N-EPIC study presented at the EULAR 2021 Congress.
Results of the phase III, placebo-controlled ProDERM trial reported at EULAR 2021 showed significant efficacy and acceptable safety for immunoglobulin therapy given intravenously (IVIg) to patients with dermatomyositis – a systemic autoimmune disease marked by progressive proximal muscle weakness and a distinctive skin rash.